文献速递脑血管病外科神经重症

重型蛛网膜下腔出血患者在高血容量、血液稀释和高血压治疗期间脑血流量变化与脑能量代谢

CBF changes and cerebral energy metabolism during hypervolemia, hemodilution, and hypertension therapy in patients with poor-grade subarachnoid hemorrhage.
PubMed 文献 · J Neurosurg · 2020-01-10

这项前瞻性观察研究在重型蛛网膜下腔出血合并迟发性脑缺血患者中,用床旁氙增强CT和脑微透析评估高血容量、血液稀释和高血压(HHH)治疗期间的脑血流量与能量代谢;12例接受HHH治疗者整体皮质脑血流量升高,能量代谢参数无统计学变化,无患者出现严重缺血。

要点

  • 合并迟发性脑缺血的重型蛛网膜下腔出血患者接受HHH治疗后整体皮质脑血流量较基线升高。
  • HHH期间脑微透析能量代谢参数(乳酸/丙酮酸比值等)无统计学变化。
  • HHH期间无患者出现严重缺血的代谢表现,但能量代谢紊乱常见,可能归因于线粒体功能障碍。

核心结论

  • 在合并迟发性脑缺血的重型蛛网膜下腔出血患者中,HHH治疗期间整体和区域脑血流量改善,脑能量代谢的脑微透析参数无统计学变化;无患者出现严重缺血的代谢表现,但能量代谢紊乱常见,原文认为可能归因于线粒体功能障碍。

研究设计与样本

  • 前瞻性观察研究;在临床怀疑迟发性脑缺血时启动为期5天的HHH治疗,需具备基线和HHH治疗期间的脑血流量测量与脑微透析数据方可纳入。
  • 脑血流量用床旁氙增强CT在第0–3天、第4–7天、第8–12天评估,脑代谢状态用脑微透析每小时分析葡萄糖、乳酸、丙酮酸和谷氨酸。
  • 接受HHH治疗的迟发性脑缺血患者12例;在相应时间窗内有测量的非迟发性脑缺血患者11例作为参照组。

主要发现

  • 接受HHH治疗的患者整体皮质脑血流量从30.4 ml/100 g/min(IQR 25.1–33.8 ml/100 g/min)升至38.4 ml/100 g/min(IQR 34.2–46.1 ml/100 g/min;p = 0.006)。
  • 能量代谢脑微透析参数无统计学变化,乳酸/丙酮酸比值基线为26.9(IQR 22.9–48.5),HHH期间为31.6(IQR 22.4–35.7)。
  • 按HHH期间能量代谢模式分类,无患者为严重缺血,8例呈符合线粒体功能障碍的紊乱,4例正常。
  • 非迟发性脑缺血参照组基线脑血流量更高、乳酸/丙酮酸比值更低,随时间无变化,全部患者代谢模式正常。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Despite the multifactorial pathogenesis of delayed cerebral ischemia (DCI) after subarachnoid hemorrhage (SAH), augmentation of cerebral blood flow (CBF) is still considered essential in the clinical management of DCI. The aim of this prospective observational study was to investigate cerebral metabolic changes in relation to CBF during therapeutic hypervolemia, hemodilution, and hypertension (HHH) therapy in poor-grade SAH patients with DCI. METHODS: CBF was assessed by bedside xenon-enhanced CT at days 0-3, 4-7, and 8-12, and the cerebral metabolic state by cerebral microdialysis (CMD), analyzing glucose, lactate, pyruvate, and glutamate hourly. At clinical suspicion of DCI, HHH therapy was instituted for 5 days. CBF measurements and CMD data at baseline and during HHH therapy were required for study inclusion. Non-DCI patients with measurements in corresponding time windows were included as a reference group. RESULTS: In DCI patients receiving HHH therapy (n = 12), global cortical CBF increased from 30.4 ml/100 g/min (IQR 25.1-33.8 ml/100 g/min) to 38.4 ml/100 g/min (IQR 34.2-46.1 ml/100 g/min; p = 0.006). The energy metabolic CMD parameters stayed statistically unchanged with a lactate/pyruvate (L/P) ratio of 26.9 (IQR 22.9-48.5) at baseline and 31.6 (IQR 22.4-35.7) during HHH. Categorized by energy metabolic patterns during HHH, no patient had severe ischemia, 8 showed derangement corresponding to mitochondrial dysfunction, and 4 were normal. The reference group of non-DCI patients (n = 11) had higher CBF and lower L/P ratios at baseline with no change over time, and the metabolic pattern was normal in all these patients. CONCLUSIONS: Global and regional CBF improved and the cerebral energy metabolic CMD parameters stayed statistically unchanged during HHH therapy in DCI patients. None of the patients developed metabolic signs of severe ischemia, but a disturbed energy metabolic pattern was a common occurrence, possibly explained by mitochondrial dysfunction despite improved microcirculation.

来源:J Neurosurg,查看原文。版权归原作者所有。

引用

  1. Engquist H, Lewén A, Hillered L, et al. CBF changes and cerebral energy metabolism during hypervolemia, hemodilution, and hypertension therapy in patients with poor-grade subarachnoid hemorrhage. J Neurosurg. 2020. PMID: 31923897. doi:10.3171/2019.11.JNS192759

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。